$6.60
0.38% today
Nasdaq, Dec 15, 09:47 pm CET
ISIN
US6700021040
Symbol
NVAX

Novavax, Inc. Stock price

$6.57
-0.63 8.75% 1M
-0.58 8.11% 6M
-1.47 18.28% YTD
-2.45 27.16% 1Y
-9.80 59.87% 3Y
-123.13 94.93% 5Y
-142.03 95.58% 10Y
-74.83 91.93% 20Y
Nasdaq, Closing price Fri, Dec 12 2025
-0.12 1.79%
ISIN
US6700021040
Symbol
NVAX
Industry

New AI Insights on Novavax, Inc. Insights AI Insights on Novavax, Inc.

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$555.9m
Net debt
positive
Cash
$762.9m
Shares outstanding
162.5m
Valuation (TTM | estimate)
P/E
3.1 | 2.9
P/S
1.0 | 1.0
EV/Sales
0.5 | 0.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-40.0%
Return on Equity
30.1%
ROCE
55.6%
ROIC
377.0%
Debt/Equity
-1.6
Financials (TTM | estimate)
Revenue
$1.1b | $1.1b
EBITDA
$451.8m | $466.5m
EBIT
$416.8m | $415.2m
Net Income
$341.8m | $373.8m
Free Cash Flow
$-383.7m
Growth (TTM | estimate)
Revenue
20.3% | 58.9%
EBITDA
285.8% | 354.3%
EBIT
243.7% | 279.0%
Net Income
220.0% | 299.4%
Free Cash Flow
-246.2%
Margin (TTM | estimate)
Gross
91.8%
EBITDA
42.4% | 43.0%
EBIT
39.2%
Net
32.1% | 34.5%
Free Cash Flow
-36.0%
More
EPS
$2.1
FCF per Share
$-2.4
Short interest
32.0%
Employees
952
Rev per Employee
$720.0k
Show more

Is Novavax, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,086 stocks worldwide.

Novavax, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Novavax, Inc. forecast:

10x Buy
67%
2x Hold
13%
3x Sell
20%

Analyst Opinions

15 Analysts have issued a Novavax, Inc. forecast:

Buy
67%
Hold
13%
Sell
20%

Financial data from Novavax, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1,065 1,065
20% 20%
100%
- Direct Costs 87 87
73% 73%
8%
978 978
73% 73%
92%
- Selling and Administrative Expenses 193 193
52% 52%
18%
- Research and Development Expense 368 368
18% 18%
35%
452 452
286% 286%
42%
- Depreciation and Amortization 35 35
25% 25%
3%
EBIT (Operating Income) EBIT 417 417
244% 244%
39%
Net Profit 342 342
220% 220%
32%

In millions USD.

Don't miss a Thing! We will send you all news about Novavax, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novavax, Inc. Stock News

Negative
The Motley Fool
4 days ago
Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either.
Neutral
Investopedia
14 days ago
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Negative
Market Watch
14 days ago
Memo also reportedly mentions vaccines for flu and pneumonia.
More Novavax, Inc. News

Company Profile

Novavax, Inc. is operates as a clinical-stage biotechnology company, which focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It produces vaccine candidates to respond to both known and emerging disease threats by using the proprietary recombinant nanoparticle vaccine technology. The firm's vaccine candidates include ResVax and NanoFlu. It also develops immune stimulating saponin-based adjuvants through its wholly owned Swedish subsidiary, Novavax AB. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Head office United States
CEO John Jacobs
Employees 952
Founded 1987
Website www.novavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today